Haemonetics Secures CE Mark Certification for VASCADE MVP® XL Venous Vascular Closure System

Haemonetics Expands European Vascular Closure Portfolio with CE Mark Certification for VASCADE MVP® XL System

Haemonetics Corporation, a global medical technology company focused on developing innovative solutions to improve patient outcomes, has announced that its VASCADE MVP® XL venous vascular closure system has received CE Mark certification under the European Union Medical Device Regulation (EU-MDR). The certification represents an important step in the company’s efforts to expand its international presence and make its vascular closure technology available to physicians and patients across Europe and other markets that recognize CE marking.

The approval allows Haemonetics to broaden the commercial reach of the VASCADE MVP XL system, which is designed to support the closure of larger femoral venous access sites following catheter-based cardiovascular procedures. The system is intended to help reduce the time patients spend recovering after procedures by supporting faster hemostasis, earlier ambulation and eligibility for hospital discharge.

The first European procedures using the VASCADE MVP XL system were performed in October. The procedures were carried out by three physicians at leading medical institutions in Germany, Italy and the United Kingdom. These initial cases mark the introduction of the system in the European clinical setting and represent an important milestone in Haemonetics’ expansion of its interventional technologies portfolio.

First European Procedures Mark the System’s Introduction

The first European procedures using VASCADE MVP XL were performed by Prof. Christian H. Heeger at Asklepios Clinic Altona in Hamburg, Germany; Prof. Claudio Tondo at Centro Cardiologico Monzino, IRCCS, in Milan, Italy; and Dr. Riyaz A. Kaba at Cromwell Hospital in London, United Kingdom.

These procedures represent the initial clinical use of the newly CE-marked system in Europe. The participating physicians and institutions provide an early introduction to the technology in markets where physicians perform catheter-based procedures that require larger venous access.

The European launch follows the system’s development and commercial use in the United States, where Haemonetics says VASCADE MVP XL has contributed to the growth of its Interventional Technologies business. The CE Mark certification now creates an opportunity for the company to extend its commercial activities into additional international markets.

The introduction is particularly relevant to electrophysiology and interventional cardiology, where catheter-based procedures may require larger vascular access sites. As these procedures are performed, physicians must manage the access site after removing the procedural sheath. Effective closure is an important part of post-procedure care because it helps control bleeding and supports the patient’s recovery.

EU-MDR Certification Expands the Approved Use of VASCADE MVP XL

The VASCADE MVP XL system has received CE Mark certification under the European Medical Device Regulation. Its approved indication covers the percutaneous closure of femoral venous access sites following catheter-based procedures involving procedural sheaths with an inner diameter of 10–12 French (F), with a maximum outer diameter of 15F.

The system is designed for use in patients with single or multiple access sites in one or both limbs. This approved indication addresses procedures that require larger-bore venous access and provides physicians with a closure option specifically designed for these access requirements.

According to Haemonetics, the VASCADE MVP XL system is intended to reduce several post-procedure time measures compared with conventional closure methods. These include time to ambulation, total post-procedure time, time to hemostasis and time to discharge eligibility.

Earlier ambulation allows appropriate patients to begin moving sooner after a procedure, while faster achievement of hemostasis helps support the management of the vascular access site. Reducing the time required to meet discharge eligibility may also help hospitals manage post-procedure care more efficiently.

The system is also designed to enable same-day discharge for appropriate patients who have undergone catheter-based procedures within its approved indication. The actual discharge decision remains dependent on the patient’s clinical condition and the treating physician’s assessment.

Designed for Larger-Bore Venous Access Procedures

One of the key features of VASCADE MVP XL is its design for procedures requiring larger venous access. Haemonetics developed the system to address closure requirements associated with procedural sheaths measuring 10–12F in inner diameter and up to 15F in maximum outer diameter.

The device uses 58% more collagen and a disc that is 9% larger than those used in the VASCADE MVP® system. These design differences provide a larger closure solution intended for procedures involving larger-bore venous access.

The expanded design is relevant to several types of catheter-based cardiovascular procedures. Examples identified by Haemonetics include cryoablation, Pulsed Field Ablation (PFA) and Left Atrial Appendage Closure (LAAC).

Cryoablation is a catheter-based technique used in cardiac electrophysiology procedures. Pulsed Field Ablation is another technology used in the treatment of certain cardiac rhythm conditions. Left Atrial Appendage Closure is an interventional procedure designed to close off the left atrial appendage. These procedures can involve venous access requirements that make appropriate vascular closure technology an important consideration in post-procedure management.

By introducing a system designed for larger-bore access, Haemonetics aims to provide physicians with an additional option within its existing vascular closure portfolio.

Haemonetics Highlights International Growth Opportunities

Commenting on the certification and the first European procedures, Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, said the VASCADE MVP XL system has supported the growth of the company’s Interventional Technologies business in the United States.

Crowley highlighted the benefits the system provides physicians when managing larger-bore venous closure, noting that its use is supported by clinical evidence. He also described the CE Mark certification and completion of the first European procedures as important developments for the company’s international expansion.

According to Crowley, Haemonetics expects the expanded availability of VASCADE MVP XL to support its commercial momentum in electrophysiology and interventional cardiology. The company intends to use the certification to reach a larger patient population and introduce its vascular closure technology into additional markets.

The announcement reflects Haemonetics’ broader effort to expand its medical technology business beyond the United States. Regulatory certification in Europe provides the company with access to markets that accept CE marking, creating opportunities to work with physicians and healthcare institutions that perform catheter-based cardiovascular procedures.

Physician Perspective on Post-Procedure Care

Prof. Dr. Christian H. Heeger, Director of the Department of Rhythmology at Asklepios Clinic Altona in Hamburg, Germany, also commented on the role of the VASCADE MVP system in post-procedure care.

Heeger said the VASCADE MVP system has become an important part of the department’s approach to managing patients after procedures. He highlighted its role in helping shorten the time to ambulation and facilitating earlier discharge for appropriate patients.

He also noted that the VASCADE MVP XL system allows physicians to apply the same closure technology in procedures requiring larger venous access, within the system’s approved indication.

His comments underline the clinical relevance of providing different closure options for procedures involving varying access-site sizes. While standard and mid-bore procedures may require one type of closure solution, larger-bore procedures can present different requirements. The availability of VASCADE MVP XL gives physicians an additional option for addressing those requirements.

The system’s introduction in Europe therefore expands the range of vascular closure technologies available within Haemonetics’ portfolio.

VASCADE MVP XL Strengthens Haemonetics’ Existing Product Portfolio

Alongside VASCADE MVP XL, Haemonetics offers two other vascular closure systems: the VASCADE® vascular closure system and the VASCADE MVP system. Together, these products are designed to address different femoral arterial and venous access requirements following catheter-based procedures.

The VASCADE vascular closure system is designed for small-bore femoral arterial and venous closure. It is intended for procedures using standard 5–6/7F procedural sheaths.

The VASCADE MVP system is designed for mid-bore, multi-access femoral venous closure. It is intended for procedures using sheaths with inner diameters ranging from 6F to 12F.

VASCADE MVP XL extends the portfolio by addressing larger-bore venous access procedures involving 10–12F inner-diameter sheaths, with a maximum outer diameter of 15F.

Both the VASCADE and VASCADE MVP systems are CE marked under the EU-MDR for use in patients who have undergone catheter-based procedures. Haemonetics states that these devices incorporate proprietary collapsible disc technology and a resorbable collagen plug to achieve hemostasis.

This shared technology approach allows the company to offer closure solutions across different procedural access requirements. Rather than relying on a single device for every procedure, physicians can select from the portfolio based on the access-site size and the needs of the procedure.

Supporting Recovery Following Catheter-Based Procedures

Vascular access management is an important part of care following interventional cardiovascular procedures. Once a catheter-based procedure is completed and the procedural sheath is removed, the access site must be managed to achieve hemostasis and support recovery.

The time required to achieve hemostasis, begin ambulation and meet discharge criteria can influence the overall post-procedure experience. Closure technologies are designed to help physicians manage these steps while addressing the requirements of different vascular access sizes.

VASCADE MVP XL is intended to support this process for larger-bore femoral venous access sites. Its approved use includes procedures involving single or multiple access sites in one or both limbs. Haemonetics says the system is designed to reduce time to hemostasis, ambulation, total post-procedure care and discharge eligibility compared with conventional closure methods.

The possibility of same-day discharge for appropriate patients is another important aspect of the system’s intended benefits. However, discharge timing depends on individual patient circumstances, procedural outcomes and clinical judgment.

A New Step in Haemonetics’ European Expansion

The CE Mark certification of VASCADE MVP XL expands Haemonetics’ vascular closure portfolio and strengthens its position in the interventional technologies market. The completion of the first European procedures in Germany, Italy and the United Kingdom demonstrates the system’s introduction into the region following regulatory certification.

With its design for larger-bore venous access, the system is intended to address closure needs associated with procedures such as cryoablation, PFA and LAAC. Its addition also complements the company’s existing small-bore and mid-bore closure systems.

Haemonetics plans to use the certification to expand its reach among physicians and healthcare institutions in Europe and other geographies that recognize CE marking. The company sees opportunities to build on the system’s commercial performance in the United States and extend its presence in electrophysiology and interventional cardiology.

The announcement marks another development in Haemonetics’ efforts to bring its vascular closure technologies to a broader international market, with a focus on supporting physicians in post-procedure care and improving the patient recovery process.

Source link: https://haemonetics.gcs-web.com/

Newsletter Updates

Enter your email address below and subscribe to our newsletter